Verve Therapeutics, Inc. (VERV)

NASDAQ: VERV · IEX Real-Time Price · USD
37.86
+2.27 (6.38%)
At close: Aug 15, 2022 4:00 PM
37.25
-0.61 (-1.61%)
After-hours: Aug 15, 2022 7:22 PM EDT
6.38%
Market Cap 2.27B
Revenue (ttm) n/a
Net Income (ttm) -125.20M
Shares Out 59.94M
EPS (ttm) 6.87
PE Ratio 5.51
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 775,708
Open 35.06
Previous Close 35.59
Day's Range 35.00 - 37.93
52-Week Range 10.70 - 78.00
Beta n/a
Analysts Buy
Price Target 52.46 (+38.6%)
Earnings Date Aug 11, 2022

About VERV

Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics, Inc.; and a C... [Read more...]

Industry Biotechnology
IPO Date Jun 17, 2021
Employees 113
Stock Exchange NASDAQ
Ticker Symbol VERV
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 14 analysts, the average rating for VERV stock is "Buy." The 12-month stock price forecast is 52.46, which is an increase of 38.56% from the latest price.

Price Target
$52.46
(38.56% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Verve Therapeutics Provides Corporate Updates and Reports Second Quarter 2022 Financial Results

Over $300 Million in Capital Added to Balance Sheet, Supporting an Operating Runway into Second Half of 2025

Verve Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise by Underwriters of ...

CAMBRIDGE, Mass., July 25, 2022 (GLOBE NEWSWIRE) -- Verve Therapeutics, Inc. (Nasdaq: VERV), a biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course ge...

Why Shares of Verve Therapeutics Shot Up 44.9% This Week

The gene-editing company is getting an infusion of cash.

Verve (VERV) Up on Gene Editing Collaboration With Vertex

Verve Therapeutics (VERV) enters into a four-year collaboration with Vertex Therapeutics to develop a gene-editing program targeted at liver disease for an upfront payment of $60 million.

Verve Therapeutics, Vertex Join Forces For Liver Disease-Focused Gene Program

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) and Verve Therapeutics Inc (NASDAQ: VERV) announced an exclusive, four-year global research collaboration to discover and develop an in vivo gene editi...

Verve Therapeutics Announces Pricing of Upsized Public Offering of Common Stock

CAMBRIDGE, Mass., July 21, 2022 (GLOBE NEWSWIRE) -- Verve Therapeutics, Inc. (Nasdaq: VERV), a biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course ge...

Verve Therapeutics Announces Proposed Public Offering of Common Stock

CAMBRIDGE, Mass., July 20, 2022 (GLOBE NEWSWIRE) -- Verve Therapeutics, Inc. (Nasdaq: VERV), a biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course ge...

Vertex and Verve Therapeutics Establish Collaboration to Discover and Develop an In Vivo Gene Editing Program for Liv...

Verve to Receive $25 Million Upfront Payment and $35 Million Equity Investment, as Well as Potential Milestones and Royalties Verve to Receive $25 Million Upfront Payment and $35 Million Equity Investme...

Verve Therapeutics Doses First Human with an Investigational In Vivo Base Editing Medicine, VERVE-101, as a Potential...

Phase 1b Clinical Trial, heart-1, Now Underway and Enrolling Patients with Heterozygous Familial Hypercholesterolemia in New Zealand

Verve Therapeutics Appoints Experienced Biotechnology Executive, Alexander G. “Bo” Cumbo, to its Board of Directors

CAMBRIDGE, Mass., June 13, 2022 (GLOBE NEWSWIRE) -- Verve Therapeutics, a biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines,...

Verve Therapeutics to Participate in the 2022 Jefferies Healthcare Conference

CAMBRIDGE, Mass., June 01, 2022 (GLOBE NEWSWIRE) -- Verve Therapeutics, a biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines,...

Verve Therapeutics Announces Clearance of First VERVE-101 Clinical Trial Application and Outlines Global Clinical Dev...

Verve on Track to Begin Dosing HeFH Patients in New Zealand in Mid-2022 in a Phase 1 Clinical Trial with Initial Clinical Data Expected in 2023

Verve Therapeutics Reports Additional VERVE-101 and GalNAc-Lipid Nanoparticle Delivery Data in Non-Human Primates at ...

VERVE-101 Preclinical Data Package Supports Company's Global Development Strategy and Regulatory Submissions for Clinical Trials in Patients with HeFH

Verve Therapeutics to Participate in Upcoming May Investor Conferences

CAMBRIDGE, Mass., May 04, 2022 (GLOBE NEWSWIRE) -- Verve Therapeutics, a biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, ...

Verve Therapeutics Presents Comprehensive Analyses of Off-target Editing Risk for VERVE-101 at Precision Genome Engin...

Extensive Analyses in Multiple Human Cell Types Demonstrate Minimal to No Off-target Editing Following VERVE-101 Treatment, Supporting its Planned Clinical Initiation in 2022

Verve Therapeutics Reports Durable and Well-Tolerated Editing of ANGPTL3 Gene Out to More than 20 Months in Non-Human...

Updated Sequential Dosing Data Show Administration of PCSK9 Base Editor Followed by ANGPTL3 Base Editor is Well-Tolerated in NHPs

Verve Therapeutics to Participate in the Guggenheim Genomic Medicines and Rare Disease Conference

CAMBRIDGE, Mass., March 24, 2022 (GLOBE NEWSWIRE) -- Verve Therapeutics, a biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines...

Verve Therapeutics Announces Pipeline Progress and Reports Fourth Quarter and Full Year 2021 Financial Results

Significant Progress Anticipated in 2022 with Initiation of Clinical Trial for VERVE-101 and IND-enabling Studies for ANGPTL3 Program

Verve Therapeutics to Present at the Cowen 42nd Annual Healthcare Conference

CAMBRIDGE, Mass., Feb. 23, 2022 (GLOBE NEWSWIRE) -- Verve Therapeutics, a biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines,...

Verve Therapeutics Announces 2022 Anticipated Milestones and Preclinical Data on Potential Additional Dosing Regimens...

VERVE-101 Regulatory Submissions and First Patient Treated On-track for Second Half of 2022

The Best CRISPR Companies to Invest In

These CRISPR stocks could be big winners for patient investors.

Other symbols: BEAMCRSPEDITNTLA

Verve Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Verve Therapeutics, a biotech company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today...

3 Synthetic Biology Stocks in Focus With Strong Potential

Here we discuss three stocks - CDXS, PGEN, VERV - engaged in the field of scientific biology that investors may keep a tab of as these have the potential to generate wealth for them going forward.

Other symbols: CDXSPGEN

These were the 10 best performing IPOs of 2021 amid a record year for stock market debuts

Global IPOs have raised $453 billion in proceeds, representing a 67% increase year-over-year and a more than doubling from 2019 levels.

Verve Therapeutics Appoints Allison Dorval, Experienced Financial Executive, as Chief Financial Officer

CAMBRIDGE, Mass., Nov. 29, 2021 (GLOBE NEWSWIRE) -- Verve Therapeutics, Inc., (Nasdaq: VERV), a biotech company pioneering a new approach to the care of cardiovascular disease with single-course gene ed...